220 related articles for article (PubMed ID: 36880596)
21. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
Ablain J; Rice K; Soilihi H; de Reynies A; Minucci S; de Thé H
Nat Med; 2014 Feb; 20(2):167-74. PubMed ID: 24412926
[TBL] [Abstract][Full Text] [Related]
22. Spironolactone-induced XPB degradation requires TFIIH integrity and ubiquitin-selective segregase VCP/p97.
Chauhan AK; Li P; Sun Y; Wani G; Zhu Q; Wani AA
Cell Cycle; 2021 Jan; 20(1):81-95. PubMed ID: 33381997
[TBL] [Abstract][Full Text] [Related]
23. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
Nasr R; de Thé H
Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
[TBL] [Abstract][Full Text] [Related]
24. SUMOylation regulates the number and size of promyelocytic leukemia-nuclear bodies (PML-NBs) and arsenic perturbs SUMO dynamics on PML by insolubilizing PML in THP-1 cells.
Hirano S; Udagawa O
Arch Toxicol; 2022 Feb; 96(2):545-558. PubMed ID: 35001170
[TBL] [Abstract][Full Text] [Related]
25. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
[TBL] [Abstract][Full Text] [Related]
26. Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function.
Bercier P; Wang QQ; Zang N; Zhang J; Yang C; Maimaitiyiming Y; Abou-Ghali M; Berthier C; Wu C; Niwa-Kawakita M; Dirami T; Geoffroy MC; Ferhi O; Quentin S; Benhenda S; Ogra Y; Gueroui Z; Zhou C; Naranmandura H; de Thé H; Lallemand-Breitenbach V
Cancer Discov; 2023 Dec; 13(12):2548-2565. PubMed ID: 37655965
[TBL] [Abstract][Full Text] [Related]
27. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
Vitaliano-Prunier A; Halftermeyer J; Ablain J; de Reynies A; Peres L; Le Bras M; Metzger D; de Thé H
Blood; 2014 Dec; 124(25):3772-80. PubMed ID: 25258343
[TBL] [Abstract][Full Text] [Related]
28. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.
Nasr R; Lallemand-Breitenbach V; Zhu J; Guillemin MC; de Thé H
Clin Cancer Res; 2009 Oct; 15(20):6321-6. PubMed ID: 19808868
[TBL] [Abstract][Full Text] [Related]
29. PML isoforms in response to arsenic: high-resolution analysis of PML body structure and degradation.
Hands KJ; Cuchet-Lourenco D; Everett RD; Hay RT
J Cell Sci; 2014 Jan; 127(Pt 2):365-75. PubMed ID: 24190887
[TBL] [Abstract][Full Text] [Related]
30. Effects of realgar (As
Niu M; Shen Y; Qi J; Liu X; Sang W; Wu Q; Cao J; Chen W; Yao Y; Xu K
Ann Hematol; 2017 Nov; 96(11):1945-1948. PubMed ID: 28821933
[No Abstract] [Full Text] [Related]
31. Autophagic degradation of an oncoprotein.
Bøe SO; Simonsen A
Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
[TBL] [Abstract][Full Text] [Related]
32. UV-induced proteolysis of RNA polymerase II is mediated by VCP/p97 segregase and timely orchestration by Cockayne syndrome B protein.
He J; Zhu Q; Wani G; Wani AA
Oncotarget; 2017 Feb; 8(7):11004-11019. PubMed ID: 28036256
[TBL] [Abstract][Full Text] [Related]
33. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
[TBL] [Abstract][Full Text] [Related]
34. Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.
Liu J; Zhu HH; Jiang H; Jiang Q; Huang XJ
Blood; 2016 Jan; 127(2):243-50. PubMed ID: 26537301
[TBL] [Abstract][Full Text] [Related]
35. Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure.
de Thé H; Pandolfi PP; Chen Z
Cancer Cell; 2017 Nov; 32(5):552-560. PubMed ID: 29136503
[TBL] [Abstract][Full Text] [Related]
36. Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia.
Hattori H; Ishikawa Y; Kawashima N; Akashi A; Yamaguchi Y; Harada Y; Hirano D; Adachi Y; Miyao K; Ushijima Y; Terakura S; Nishida T; Matsushita T; Kiyoi H
PLoS One; 2018; 13(10):e0204850. PubMed ID: 30289902
[TBL] [Abstract][Full Text] [Related]
37. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H
Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
[TBL] [Abstract][Full Text] [Related]
38.
Esnault C; Rahmé R; Rice KL; Berthier C; Gaillard C; Quentin S; Maubert AL; Kogan S; de Thé H
Blood; 2019 Mar; 133(13):1495-1506. PubMed ID: 30674471
[TBL] [Abstract][Full Text] [Related]
39. The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability.
Yang WC; Shih HM
Oncogene; 2013 Oct; 32(43):5167-75. PubMed ID: 23208507
[TBL] [Abstract][Full Text] [Related]
40. SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome.
Cao X; Clavijo C; Li X; Lin HH; Chen Y; Shih HM; Ann DK
Mol Cancer Ther; 2008 Apr; 7(4):923-34. PubMed ID: 18413806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]